hypolipidemic agents

Preferred Label : hypolipidemic agents;

MeSH definition : Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.;

MeSH synonym : agents, hypolipidemic; drugs, antilipemic; antilipemic drugs; antilipemics; agents, antilipemic; antihyperlipidemics; antihyperlipemics; antilipemic agents; hypolipidemic drugs; drugs, hypolipidemic; Antihyperlipidemic; Antilipemic Drug; Drug, Antilipemic; Hypolipidemic Drug; Drug, Hypolipidemic; Antilipemic; Hypolipidemic Agent; Agent, Hypolipidemic;

Wikipedia automatic translation : Lipid-lowering agent;

Wikipedia link : https://en.wikipedia.org/wiki/Lipid-lowering agent;

Is substance : O;

action pharmacologique : O;

Details

Origin ID

D000960;

UMLS CUI

C0086440;

ATC code(s)
- Combinations of various lipid modifying agents [ATC Code]
- Lipid modifying agents in combination with other drugs [ATC Code]
- lipid modifying agents [ATC Code]
- lipid modifying agents, combinations [ATC Code]
- lipid modifying agents, plain [ATC Code]
- nicotinyl alcohol (pyridylcarbinol) [ATC Code]
- other lipid modifying agents [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- Antilipemic agent (substance) [SNOMED CT concept]
Currated CISMeF NLP mapping
- Antihyperlipidemic drug [ICD-11 Extension code]
- Lipid lowering agents [LOINC hierarchical part]
- antilipemic agent, nos [SNOMED Notion]
Indexing information
- (Z)-N-(2-hydroxyethyl) docos-13-enamide [MeSH Supplementary Concept]
- 2-phenylethyl 2,6-dihydroxybenzoate [MeSH Supplementary Concept]
- 8-dehydroxymethylvisanol [MeSH Supplementary Concept]
- 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid [MeSH Supplementary Concept]
- 9-O-(3-O-acetyl-beta-D-glucopyranosyl)-4-hydroxycinnamic acid [MeSH Supplementary Concept]
- F1 CX3CR1 ligand peptide [MeSH Supplementary Concept]
- calophyllic acid [MeSH Supplementary Concept]
- canophyllic acid [MeSH Supplementary Concept]
- isosorbide-5-nicotinate-2-aspirinate [MeSH Supplementary Concept]
- pseudoberberine [MeSH Supplementary Concept]
- simcor [MeSH Supplementary Concept]
Metaterm(s)
- endocrinology [CISMeF Metaterm]
Record concept(s)
- hypolipidemic agents [MeSH concept]
See also
- lipids [MeSH Descriptor]
See also (suggested by CISMeF)
- hyperlipidemias [MeSH Descriptor]
See also inter- (CISMeF)
- Antilipemic drug [ICD-11 Extension code]
- Medicinal product acting as antilipemic agent (product) [SNOMED CT concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- 4'-chlorodiazepam [MeSH Supplementary Concept]
- 5-(tetradecyloxy)-2-furancarboxylic acid [MeSH Supplementary Concept]
- 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid [MeSH Supplementary Concept]
- MEDICA 16 [MeSH Supplementary Concept]
- MK-1293 [MeSH Supplementary Concept]
- N-((1S,trans)-2-hydroxycyclopentyl)adenosine [MeSH Supplementary Concept]
- acipimox [MeSH Supplementary Concept]
- allicin [MeSH Supplementary Concept]
- beclobrate [MeSH Supplementary Concept]
- bendazac lysine [MeSH Supplementary Concept]
- benfluorex [MeSH Supplementary Concept]
- bezafibrate [MeSH Descriptor]
- binifibrate [MeSH Supplementary Concept]
- butoxamine [MeSH Descriptor]
- cholestane-3,5,6-triol [MeSH Supplementary Concept]
- ciprofibrate [MeSH Supplementary Concept]
- clofenapate [MeSH Descriptor]
- colestipol [MeSH Descriptor]
- diallyl trisulfide [MeSH Supplementary Concept]
- etiroxate [MeSH Supplementary Concept]
- etofylline clofibrate [MeSH Supplementary Concept]
- evening primrose oil [MeSH Supplementary Concept]
- fenofibrate [MeSH Descriptor]
- gamma-oryzanol [MeSH Supplementary Concept]
- gamma-sitosterol [MeSH Supplementary Concept]
- gemfibrozil [MeSH Descriptor]
- ginsenoside Rb2 [MeSH Supplementary Concept]
- glucuronyl glucosamine glycan sulfate [MeSH Supplementary Concept]
- guggulu extract [MeSH Supplementary Concept]
- halofenate [MeSH Descriptor]
- laminaran [MeSH Supplementary Concept]
- magnesium-pyridoxal-5'-phosphate glutamate [MeSH Supplementary Concept]
- nafenopin [MeSH Descriptor]
- niacin [MeSH Descriptor]
- niceritrol [MeSH Descriptor]
- plafibride [MeSH Supplementary Concept]
- polyene phosphatidylcholine [MeSH Supplementary Concept]
- pyridinolcarbamate [MeSH Descriptor]
- seladelpar [MeSH Supplementary Concept]
- tiadenol [MeSH Supplementary Concept]
- triparanol [MeSH Descriptor]
- xanthurenic acid [MeSH Supplementary Concept]
- xymedon [MeSH Supplementary Concept]
UMLS correspondences (same concept)
- Antihyperlipidemic drug [ICD-11 Extension code]
- Antilipemic agent (substance) [SNOMED CT concept]
- Lipid lowering agents [LOINC hierarchical part]
- Medicinal product acting as antilipemic agent (product) [SNOMED CT concept]
Validated automatic mappings to NTBT
- Antihyperlipidemic and antiarteriosclerotic drugs [Bloc CIM-11]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients